Dr. Sean Matthew Blaydon, MD

Dr. Blaydon practices at Texas Oculoplastic Consultants PLLC in Austin, Texas.

Dr. Blaydon's NPI, 1730170622, was assigned on October 31, 2005. Dr. Blaydon graduated from Tulane School of Medicine in 1989. Dr. Blaydon holds Texas license K4374.

Dr. Blaydon's primary practice is Texas Oculoplastic Consultants PLLC, at 3705 Medical Pkwy, Austin, TX 78705 in Travis County. The practice phone is (512) 458-2141.

Dr. Blaydon's primary practice is Texas Oculoplastic Consultants PLLC in Austin, Texas. Dr. Blaydon is also affiliated with Ascension Seton Medical Center Austin. Dmand AI also links Dr. Blaydon to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Blaydon practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmic plastic and reconstructive surgery is Dr. Blaydon's primary specialty in the NPI Registry, under taxonomy code 207WX0200X. Dr. Blaydon is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Blaydon's licenses on file in 4 states: Texas, California, Pennsylvania and Louisiana.

Dmand AI lists conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation and vision problems among the conditions Dr. Blaydon treats.

CMS data shows 4,324 Medicare services from Dr. Blaydon across 13 procedure codes in 2024, for 368 Medicare patients. Medicare paid $127,111 for them.

CMS counts 368 Medicare patients who saw Dr. Blaydon in 2024. The largest group is 65 to 74, with 181 patients. 75% of them have high cholesterol, and 69% have high blood pressure. Their average risk score is 0.93, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Blaydon's median patient age at 68, with 61% women.

In 2024, Dr. Blaydon wrote 479 Medicare Part D claims for 291 patients. 97% of them were for generic drugs. CMS names the drug for 459 of them, across 5 drugs with 11 or more claims each, at $5,902 in total drug cost. In 2023, CMS named 414 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 59 out of 100 for Dr. Blaydon for performance year 2024, reported individually. Dr. Blaydon accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 20 papers to Dr. Blaydon, published from 2014 to 2022. 2022 was the busiest year, with 2. The most frequent topics are Eyelids, Blepharoptosis and Oculomotor Muscles. Dr. Blaydon has published most often in Ophthalmic Plast Reconstr Surg. Dr. Blaydon's most frequent co-authors are John W. Shore, MD, Vikram David Durairaj, MD and Malena M. Amato, MD.

CMS Open Payments shows 68 general payments to Dr. Blaydon from 29 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 95% of the total. TissueTech, Inc. paid the most, $642.

Dmand AI lists 3 awards for Dr. Blaydon, most recently CMS Stage 1 EHR in 2013.

Dr. Blaydon graduated from Tulane School of Medicine in 1989. Dr. Blaydon is a member of AAO and ACS.

Dr. Blaydon is in network with 21 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.